Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat, Isotretinoin, and Temozolomide in Recurrent Glioblastoma
NCT00555399Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2007
- Primary completion
- Jan 2020
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of vorinostat in glioblastoma (GBM) and Gliosarcoma (GS) (3 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Maximum Tolerated Dose at 62 months and Time to Progression. Started Nov 2007; status: terminated.
02
Drugs
vorinostat
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT00555399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00555399.